CAS 16684-06-3: D-erythro-a-D-galacto-Octopyranoside, methyl7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-(9CI)

Impurity Clindamycin EP Impurity C Applications 7-Epiclindamycin (Clindamycin EP Impurity C) is an epimer of Clindamycin (C580000), which is a semi-synthetic antibiotic prepared from Lincomycin, an antibacterial. In addition, 7-Epiclindamycin is an intermediate in synthesizing 7-Epiclindamycin 2-Phosphate (>90%) (E582505), which is an another impurity of Clindamycin. References Birkenmeyer, R., et al.: J. Med. Chem., 13, 616 (1970), Platzer, D., et al.: J. Pharm. Biomed. Anal., 41, 84 (2006), Platzer, D., et al.: J. Pharm. Biomed. Anal., 41, 84 (2006); Oesterling, et al.: J. Pharm. Sci., 59, 63 (1970); Gray, J.E., et al.: Toxicol. Appl. Pharmacol., 21, 516 (1972); Brown, L.W., et al.: Anal. Profiles Drug Subs., 10, 75 (1981)

7-epi-Clindamycin is a clindamycin derivative, which is a semisynthetic antibiotic derived from the bacterium *Streptomyces lincolnensis*. Its mode of action involves binding to the 50S subunit of the bacterial ribosome, thereby inhibiting protein synthesis. This results in the suppression of bacterial growth, making it effective against certain Gram-positive bacteria and anaerobic species. In the context of microbial pharmacology and medicinal chemistry, 7-epi-Clindamycin is particularly noted for its potential in combating bacterial infections that are resistant to other antibiotics. It is of interest in scientific studies focusing on antibiotic resistance and the development of new therapeutic agents. Its applications extend to research settings where detailed mechanisms of antibiotic action are explored, as well as in the characterization of new antibiotic derivatives. Through its structural influence on ribosomal function, it serves as a critical tool for understanding bacterial physiology and the development of resistance.